# RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

> **NCT02452970** · PHASE2 · TERMINATED · sponsor: **EpicentRx, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** RRx-001
- **DRUG:** Gemcitabine and cisplatin

## Key facts

- **NCT ID:** NCT02452970
- **Lead sponsor:** EpicentRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-16
- **Primary completion:** 2016-05-10
- **Final completion:** 2016-05-25
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Poor enrollment and adverse event experiences in the limited population
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452970, "RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02452970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*